Treatment of acute graft-versus-host disease with
prednisolone: significant survival advantage for day +5
responders and no advantage for nonresponders receiving
anti–thymocyte globulin
by Maria Teresa Van Lint, Giuseppe Milone, Salvatore Leotta, Cornelio Uderzo,
Rosanna Scimè, Sandro Dallorso, Anna Locasciulli, Stefano Guidi, Nicola Mordini,
Simona Sica, Laura Cudillo, Franca Fagioli, Carmine Selleri, Barbara Bruno, William
Arcese, and Andrea Bacigalupo
Blood
Volume 107(10):4177-4181
May 15, 2006
©2006 by American Society of Hematology
Trial design: all patients with a diagnosis of acute graft-versus-host disease (GvHD) are treated
with 6MPred 2 mg/kg per day from day 1 to day 5.
Maria Teresa Van Lint et al. Blood 2006;107:4177-4181
©2006 by American Society of Hematology
Effect of response to first-line therapy on outcome.
Maria Teresa Van Lint et al. Blood 2006;107:4177-4181
©2006 by American Society of Hematology
Identifying patients in different risk groups after first-line therapy.
Maria Teresa Van Lint et al. Blood 2006;107:4177-4181
©2006 by American Society of Hematology
Response rates to second-line therapy.
Maria Teresa Van Lint et al. Blood 2006;107:4177-4181
©2006 by American Society of Hematology
The effect of ATG given as second-line therapy on outcome.
Maria Teresa Van Lint et al. Blood 2006;107:4177-4181
©2006 by American Society of Hematology